BRPI0609692B8 - processos de fermentação e de fabricação de uma preparação de um antígeno de c. diphtheriae - Google Patents

processos de fermentação e de fabricação de uma preparação de um antígeno de c. diphtheriae Download PDF

Info

Publication number
BRPI0609692B8
BRPI0609692B8 BRPI0609692A BRPI0609692A BRPI0609692B8 BR PI0609692 B8 BRPI0609692 B8 BR PI0609692B8 BR PI0609692 A BRPI0609692 A BR PI0609692A BR PI0609692 A BRPI0609692 A BR PI0609692A BR PI0609692 B8 BRPI0609692 B8 BR PI0609692B8
Authority
BR
Brazil
Prior art keywords
fermentation
diphtheriae
antigen preparation
manufacturing processes
antigen
Prior art date
Application number
BRPI0609692A
Other languages
English (en)
Inventor
Roger Fernand Orval Marc
Marc Serge Ghislain Laloux Olivier
Marc Helene Dehottay Philippe
Dessoy Sandrine
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BRPI0609692A2 publication Critical patent/BRPI0609692A2/pt
Publication of BRPI0609692B1 publication Critical patent/BRPI0609692B1/pt
Publication of BRPI0609692B8 publication Critical patent/BRPI0609692B8/pt
Publication of BRPI0609692C1 publication Critical patent/BRPI0609692C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

processos de fermentação, de fabricação de uma preparação de um antígeno de c. diphtheriae e de fabricação de uma composição farmacêutica, e, usos do antígeno, toxina de dipteria ou mutante da mesma, e de uma composição farmacêutica. a presente invenção refere-se a um processo de fermentação compreendendo uma etapa de fermentação de cultivo de uma cepa de corynebacterium diphtheria em meio em um fermentador sob condições de agitação suficientes para manter uma cultura homogênea e aeração limitada, de modo que o po2 dentro da cultura cai a menos de 4% na maior parte da etapa de fermentação.
BRPI0609692A 2005-03-23 2006-03-21 processos de fermentação e de fabricação de uma preparação de um antígeno de c. diphtheriae BRPI0609692C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0505996.9 2005-03-23
GBGB0505996.9A GB0505996D0 (en) 2005-03-23 2005-03-23 Fermentation process
PCT/EP2006/002835 WO2006100108A1 (en) 2005-03-23 2006-03-21 Fermentation process for the production of diphtheria toxin

Publications (4)

Publication Number Publication Date
BRPI0609692A2 BRPI0609692A2 (pt) 2010-04-20
BRPI0609692B1 BRPI0609692B1 (pt) 2019-02-12
BRPI0609692B8 true BRPI0609692B8 (pt) 2020-01-21
BRPI0609692C1 BRPI0609692C1 (pt) 2021-05-25

Family

ID=34531759

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0609692A BRPI0609692C1 (pt) 2005-03-23 2006-03-21 processos de fermentação e de fabricação de uma preparação de um antígeno de c. diphtheriae

Country Status (14)

Country Link
US (2) US20080193475A1 (pt)
EP (2) EP2174950B1 (pt)
JP (1) JP4917087B2 (pt)
KR (1) KR101341121B1 (pt)
CN (1) CN101180313B (pt)
AT (2) ATE540053T1 (pt)
AU (1) AU2006226542B2 (pt)
BR (1) BRPI0609692C1 (pt)
CA (1) CA2602143C (pt)
DE (1) DE602006010676D1 (pt)
ES (2) ES2378193T3 (pt)
GB (1) GB0505996D0 (pt)
RU (1) RU2394914C2 (pt)
WO (1) WO2006100108A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0916365A2 (pt) * 2008-07-21 2018-05-02 Brigham & Womens Hospital Inc métodos e composições relacionados aos oligossacarídeos de glicosina beta-1,6 sintéticos
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
CN104379170B (zh) 2012-06-20 2017-05-03 国立大学法人东京大学 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物
CN103627758B (zh) * 2012-08-28 2018-04-27 天士力医药集团股份有限公司 一种crm197蛋白的生产方法
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
AR095425A1 (es) 2013-03-15 2015-10-14 Glaxosmithkline Biologicals Sa Vacuna, uso y procedimiento para prevenir una infección por picornavirus
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018156465A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
KR102637436B1 (ko) * 2017-04-22 2024-02-15 바이오로지칼 이 리미티드 Crm197의 높은 수준의 생산을 위한 개선된 방법
EP3699263A1 (en) 2019-02-22 2020-08-26 GlaxoSmithKline Biologicals S.A. Fermentation process
CN110452838B (zh) * 2019-07-18 2020-12-29 艾美卫信生物药业（浙江）有限公司 一种crm197菌种培养基、配制方法及发酵培养方法
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
CN114806973B (zh) * 2022-06-08 2024-02-23 艾美坚持生物制药有限公司 一种提高crm197蛋白产量的生长因子及其制备方法和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
JP3237842B2 (ja) 1988-12-16 2001-12-10 オランダ国 ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
DE69132581T3 (de) 1990-03-02 2008-07-17 Boston Medical Center Corp., Boston Verbesserte chimäre toxine
DE69133276T2 (de) 1990-07-16 2003-11-27 Univ North Carolina Mit der familie der hämolysin-toxine verwandte antigene eisen-ubnterdrückende proteine des n. meningitis
CA2087958C (en) 1990-08-23 2007-05-15 P. Frederick Sparling Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
ATE245446T1 (de) 1992-02-11 2003-08-15 Jackson H M Found Military Med Dualer träger für immunogene konstrukte
JP3506431B2 (ja) 1992-05-06 2004-03-15 プレジデント アンド フェローズ オブ ハーバード カレッジ ジフテリア毒素受容体結合領域
NZ253065A (en) 1992-05-23 1996-10-28 Smithkline Beecham Biolog Combination vaccines comprising hepatitis b surface antigens and other antigens wherein aluminium phosphate adjuvant is used to adsorb the hepatitis antigen
AU671649B2 (en) * 1992-06-18 1996-09-05 President And Fellows Of Harvard College Diphtheria toxin vaccines
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
SG47725A1 (en) * 1992-10-27 1998-04-17 American Cyanamid Co Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
DE69434079T2 (de) 1993-03-05 2005-02-24 Wyeth Holdings Corp. Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin
WO1994026304A1 (en) 1993-05-18 1994-11-24 Ohio State Research Foundation Otitis media vaccine
US5917017A (en) * 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
JPH11507214A (ja) 1995-06-07 1999-06-29 バイオケム ヴァシーンズ インク． Ｈｓｐ７０ファミリーに属する連鎖球菌の熱ショック蛋白質メンバー
SI1082965T1 (sl) 1995-06-23 2009-08-31 Glaxosmithkline Biolog Sa Sestavek cepiva, ki vsebuje antigen konjugata polisaharida, adsorbiranega na aluminijevem fosfatu
EP0912608B1 (en) 1996-05-01 2006-04-19 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
EP1770164B1 (en) 1996-10-31 2010-09-01 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
KR100619350B1 (ko) 1997-07-21 2006-09-05 박스터 헬쓰케어 에스.에이. 변형 면역성 뉴멀리신 백신조성물
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
CN1200731C (zh) 1998-04-07 2005-05-11 免疫医疗公司 用作疫苗的肺炎球菌胆碱结合蛋白衍生物
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
DK1535928T3 (da) 1998-10-22 2008-10-20 Univ Montana Vaccinesammensætninger indeholdende Omp85-proteiner af Neisseria gonorrhoeae og Neisseria meningitidis
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
KR100401423B1 (ko) 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
WO2006042542A2 (en) * 2004-10-19 2006-04-27 Statens Serum Institut Production of tetanus, diphtheria, and pertussis toxins and toxoids using fermentation media containing no components of animal or soy origin
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
ATE449788T1 (de) 2009-12-15
CA2602143A1 (en) 2006-09-28
BRPI0609692A2 (pt) 2010-04-20
RU2394914C2 (ru) 2010-07-20
CN101180313A (zh) 2008-05-14
WO2006100108A1 (en) 2006-09-28
CN101180313B (zh) 2012-10-03
EP1861420A1 (en) 2007-12-05
BRPI0609692B1 (pt) 2019-02-12
ATE540053T1 (de) 2012-01-15
GB0505996D0 (en) 2005-04-27
AU2006226542A1 (en) 2006-09-28
KR101341121B1 (ko) 2013-12-12
RU2007135122A (ru) 2009-04-27
JP4917087B2 (ja) 2012-04-18
AU2006226542B2 (en) 2012-02-09
EP2174950B1 (en) 2012-01-04
CA2602143C (en) 2016-08-09
ES2378193T3 (es) 2012-04-09
DE602006010676D1 (de) 2010-01-07
ES2335133T3 (es) 2010-03-22
EP1861420B1 (en) 2009-11-25
US20080193475A1 (en) 2008-08-14
KR20070116132A (ko) 2007-12-06
US20140242635A1 (en) 2014-08-28
BRPI0609692C1 (pt) 2021-05-25
JP2008533980A (ja) 2008-08-28
EP2174950A1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
BRPI0609692B8 (pt) processos de fermentação e de fabricação de uma preparação de um antígeno de c. diphtheriae
Jakubowski Aminoacyl thioester chemistry of class II aminoacyl-tRNA synthetases
ATE331731T1 (de) Verfahren zur herstellung von diphtheria toxin
BRPI0908686B8 (pt) método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas
WO2007047859A3 (en) Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
BRPI0210568B8 (pt) conjugado, uso de um conjugado, e, composição farmacêutica
WO2006037787A3 (en) Vlp-antigen conjugates and their uses as vaccines
BRPI9610511B8 (pt) construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica.
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
BRPI0718533B8 (pt) composição compreendendo ácido rosmarínico e micro-organismo contendo ou produzindo enzima hidrolítica, seu uso e processo para preparar composição tendo bioeficácia aumentada
WO2007052168A3 (en) Fed batch culture methods for streptococci
BRPI0519923A2 (pt) polipeptìdeo, seqüência de dna, vetor de dna, anticorpo, bactéria, método para produzir lps parcialmente 3-o-desacilado, composição, usos da bactéria, e de lps de bordetella isolado compreendendo lps pelo menos parcialmente 3-o-desacilado, vacina, e , método in vitro para a desacilação de lps gram-negativo ou de composições compreendendo lps gram-negativo
WO2001023421A3 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
BR0316757A (pt) Composições de meio de cultura de célula, processo para a cultura de célula progenitoras e/ou tronco, processo para a produção de mioblastos, população de células, e uso de mioblastos
BR112018009343A2 (pt) método de aperfeiçoamento da produção de biomassa e/ou da taxa de crescimento de um micro-organismo em um processo de fermentação, tanque de fermentação e composição
BR0201520A (pt) Método para produzir uma subst ncia de marcação utilizando um microorganismo
BRPI0417076A (pt) produção da toxina da difteria
WO2011151841A1 (en) Fermentation process for streptococcus pneumoniae
MD3101G2 (ro) Procedeu de obţinere a biomasei de Spirulina platensis
BRPI0510950A (pt) membro de ligação especìfico, composição farmacêutica, método para o tratamento de um tumor em um paciente, uso de um membro de ligação, produtos, ácido nucleico, e, carboidrato de sialiltetraosila
BRPI0418482A (pt) processo para o preparo de l-aminoácidos com amplificação do gene zwf
Beri et al. Comparability studies of hemin from two different origins porcine and bovine in the production of Haemophilus influenzae type b (Hib) polysaccharide
MD3129G2 (ro) Procedeu de obţinere a biomasei cianobacteriei Spirulina platensis
MX2007003954A (es) Conjugados de antigeno de particula tipo virus y su uso como vacunas.
KR20110076217A (ko) 혼합 배양을 이용한 미생물의 배양방법

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2161 EM 05/06/2012

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/02/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2510 DE 12/02/2019 QUANTO AO INVENTOR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/03/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF